Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 7
Submit an article Journal homepage
489
Views
17
CrossRef citations to date
0
Altmetric
Letters to the Editor

Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI)

Stefano MolicaDepartment Oncology-Hematology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy; Correspondence[email protected]
,
Diana GiannarelliIRCCS Regina Elena, Biostatistic Unit, Rome, Italy;
,
Luciano LevatoDepartment Oncology-Hematology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy;
,
Rosanna MirabelliDepartment Oncology-Hematology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy;
,
Massimo GentileAzienda Ospedaliera di Cosenza, U.O.C. di Ematologia, Cosenza, Italy
&
Fortunato MorabitoAzienda Ospedaliera di Cosenza, U.O.C. di Ematologia, Cosenza, Italy
Pages 1736-1739 | Received 13 Aug 2016, Accepted 31 Oct 2016, Published online: 22 Nov 2016

References

  • Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121:1403–1412.
  • Wierda WG, O’Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109:4679–4685.
  • Wierda WG, O'Brien S, Wang X, et al. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol. 2011;29:4088–4095.
  • Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124:49–62.
  • Gentile M, Shanafelt TD, Cutrona G, et al. A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. Leukemia. 2016;30:1440–1443.
  • International CLL-IPI. working group An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17:779–790.
  • Gentile M, Shanafelt TD, Rossi D, et al. Validation of the CLL-IPI and comparison with the MDACC prognostic index: analysis of 1364 newly diagnosed patients. Blood. 2016;128:2093–2095.
  • da Cunha-Bang C, Christiansen I, Niemann CU. The International prognostic Index for patients with chronic lymphocytic leukemia (CLL-IPI) applied in a population-based cohort. Blood. 2016;128:2181–2183.
  • Molica S, Shanafelt TD, Giannarelli D, et al. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: independent validation in a prospective cohort of early stage patients. Am J Hematol. 2016;91:1090–1095.
  • Molica S, Mauro FR, Callea V, et al. The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. Haematologica. 2010 Mar;95:464–469.
  • Molica S, Giannarelli D, Mirabelli R, et al. Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model. Eur J Haematol. 2016 Jan;96:72–77.
  • Hallek M, Cheson BD, Catovsky D, et al. International workshop on chronic lymphocytic leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
  • Trialists’ Collaborative Group CLL. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst. 1999;91:861.
  • Schweighofer CD, Cymbalista F, Muller C, et al. Early versus deferred treatment with combined fludarabine cyclophosphamide and rituximab (FCR) improves event-free survival in patients with high-risk binet stage A chronic lymphocytic leukemia – first results of a randomized German-French cooperative phase III trial. Am Soc Hematol, New Orleans 7–10, 2013; abstr. 524.
  • Langerbeins P, Bahlo J, Rhein C, et al. Ibrutinib in early stage CLL: preliminary results of a placebo controlled phase III study. ASH, 57th Annual Meeting and Exposition, Orlando, FL, December 5–8,2015, abstr 2934.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.